TBIO vs. PRPO, TLIS, AXDX, HLTH, OMIC, MBRX, AEZS, AKTX, ERNA, and GRTX
Should you be buying Telesis Bio stock or one of its competitors? The main competitors of Telesis Bio include Precipio (PRPO), Talis Biomedical (TLIS), Accelerate Diagnostics (AXDX), Cue Health (HLTH), Singular Genomics Systems (OMIC), Moleculin Biotech (MBRX), Aeterna Zentaris (AEZS), Akari Therapeutics (AKTX), Eterna Therapeutics (ERNA), and Galera Therapeutics (GRTX). These companies are all part of the "medical" sector.
Precipio (NASDAQ:PRPO) and Telesis Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.
Precipio received 263 more outperform votes than Telesis Bio when rated by MarketBeat users. Likewise, 73.32% of users gave Precipio an outperform vote while only 52.94% of users gave Telesis Bio an outperform vote.
Precipio has higher earnings, but lower revenue than Telesis Bio. Precipio is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Precipio currently has a consensus price target of $40.00, indicating a potential upside of 589.66%. Given Telesis Bio's higher probable upside, equities research analysts plainly believe Precipio is more favorable than Telesis Bio.
In the previous week, Telesis Bio had 1 more articles in the media than Precipio. MarketBeat recorded 1 mentions for Telesis Bio and 0 mentions for Precipio. Telesis Bio's average media sentiment score of 0.00 equaled Precipio'saverage media sentiment score.
10.5% of Precipio shares are held by institutional investors. Comparatively, 37.6% of Telesis Bio shares are held by institutional investors. 10.6% of Precipio shares are held by company insiders. Comparatively, 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Precipio has a net margin of -38.51% compared to Precipio's net margin of -173.78%. Telesis Bio's return on equity of -51.75% beat Precipio's return on equity.
Precipio has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.
Summary
Precipio beats Telesis Bio on 8 of the 15 factors compared between the two stocks.
Get Telesis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telesis Bio Competitors List
Related Companies and Tools
